FDA 483 OBSERVATION · #1188 OF 1,932 MOST-CITED

Manufacturer instructions not followed

FDA cited this observation 13 times across 12 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Human Tissue for Transplantation13
BY FISCAL YEAR
FY20253
FY20242
FY20233
FY20211
FY20193
FY20161

How FDA worded it — real examples

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

Creative Testing Solutions · Tempe, Arizona · Human Tissue for Transplantation · 2025-08-29

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

NCFMC, a Medical Corporation · Sacramento, California · Human Tissue for Transplantation · 2025-08-19

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

Eurofins Donor & Product Testing, LLC, San Ramon · San Ramon, California · Human Tissue for Transplantation · 2025-07-18

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

Donor Services Laboratory, Inc. Las Vegas · Las Vegas, Nevada · Human Tissue for Transplantation · 2024-04-12

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

Eurofins Donor & Product Testing Inc Dallas · Dallas, Texas · Human Tissue for Transplantation · 2024-03-05

Testing for communicable disease agents was not performed in accordance with the manufacturer's instructions.

California Fertility Experts-Hanabusa IVF · San Diego, California · Human Tissue for Transplantation · 2023-08-25

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →